Search results for "Specific antibody"
showing 4 items of 14 documents
Antibody synthesis in roach (Rutilus rutilus); analysis of antibody secreting cells in lymphoid organs with ELISPOT-assay
1994
The roach (Rutilus rutilus L.) which is a cyprinid fish, was immunised with bovine γ-globulin (BGG) and the antibody synthesis was studied by counting the number of specific antibody secreting cells (SASC) in the spleen and anterior kidney, and by measuring the antibody concentration in the circulation. SASCs and the total number of immunoglobulin secreting cells (TISC) were counted with the ELISPOT (enzyme-linked immunospot) assay, and anti-BGG antibodies and the concentration of immunoglobulin in sera were assayed by ELISA (enzyme-linked immunosorbent assay). The present modification of the ELISPOT-assay takes advantage of biotin-avidin amplification and yields easily detectable and nonfa…
Kininogen binding protein p33/gC1qR is localized in the vesicular fraction of endothelial cells
1996
AbstractThe endothelial protein p33/gC1qR is thought to mediate the assembly of components of the kinin-forming and complement-activating pathways on the surface of cardiovascular cells. FACS analysis of intact human umbilical vein endothelial cells using specific antibodies to p33 revealed a minor fluorescence on the cell surface whereas permeabilized cells showed a bright fluorescence indicative of an intracellular localization of p33. Immunostaining of fixed cells confirmed the predominant intracellular localization of p33. Fractionation studies demonstrated that the vesicular but not the membrane fraction of EA.hy926 cells is rich in p33. We conclude that externalization of p33 must pre…
Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy
2018
The approval of the first two monoclonal antibodies targeting CD38 (daratumumab) and SLAMF7 (elotuzumab) in late 2015 for treating relapsed and refractory multiple myeloma (RRMM) was a critical advance for immunotherapies for multiple myeloma (MM). Importantly, the outcome of patients continues to improve with the incorporation of this new class of agents with current MM therapies. However, both antigens are also expressed on other normal tissues including hematopoietic lineages and immune effector cells, which may limit their long-term clinical use. B cell maturation antigen (BCMA), a transmembrane glycoprotein in the tumor necrosis factor receptor superfamily 17 (TNFRSF17), is expressed a…
The inhibitors - a challenge for the management of patients with hereditary haemophilia A.
2018
Abstract Introduction. Our research strategy was aimed at evaluating the possible implication of the type of factor VIII product administered as substitution treatment to haemophilia A patients in the occurrence of inhibitors and their consequences on the management. Methods. Scientific articles from July 2015 to July 2017 were searched using the PubMed and PubMed Central databases. The used search terms included “haemophilia A”, “inhibitors”, “plasma-derived factor VIII” and “recombinant factor VIII”. Results. The risk factors for inhibitors occurrence may be patients-related (genetic and nongenetic) and treatment-related. The possibility of a correlation between the increased purity of fa…